AxoGen ($AXGN) raised $18 million in a public offering and has shifted to Nasdaq. Plans call for using the money to expand commercialization and marketing efforts for the Florida company's nerve repair devices and products. Funds will also help propel new product development. CEO Karen Zaderej said in a statement that the move to Nasdaq "places AxoGen among the leading innovative growth companies." Item